Q2 2024 Earnings Estimate for Entrada Therapeutics, Inc. (NASDAQ:TRDA) Issued By HC Wainwright

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Equities researchers at HC Wainwright increased their Q2 2024 earnings per share estimates for shares of Entrada Therapeutics in a research report issued on Tuesday, June 25th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.05) for the quarter, up from their prior estimate of ($0.06). HC Wainwright currently has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q3 2024 earnings at ($0.23) EPS, Q4 2024 earnings at ($0.65) EPS, FY2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.87) EPS, Q2 2025 earnings at ($0.92) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.02) EPS and FY2025 earnings at ($3.77) EPS.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock opened at $14.10 on Thursday. The company has a market capitalization of $476.02 million, a PE ratio of 22.38 and a beta of -0.23. Entrada Therapeutics has a one year low of $10.75 and a one year high of $18.44. The business has a 50 day simple moving average of $14.49 and a 200 day simple moving average of $14.29.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $1.06. The company had revenue of $59.12 million during the quarter, compared to the consensus estimate of $25.00 million. Entrada Therapeutics had a return on equity of 9.73% and a net margin of 14.42%.

Insider Buying and Selling at Entrada Therapeutics

In other news, CEO Dipal Doshi sold 1,800 shares of Entrada Therapeutics stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $15.00, for a total value of $27,000.00. Following the completion of the sale, the chief executive officer now directly owns 338,575 shares of the company’s stock, valued at approximately $5,078,625. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Peter S. Kim acquired 2,600 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was acquired at an average cost of $13.57 per share, with a total value of $35,282.00. Following the completion of the purchase, the director now directly owns 62,936 shares in the company, valued at $854,041.52. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Dipal Doshi sold 1,800 shares of Entrada Therapeutics stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $15.00, for a total value of $27,000.00. Following the sale, the chief executive officer now directly owns 338,575 shares of the company’s stock, valued at $5,078,625. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,475 shares of company stock worth $205,133. 7.58% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Entrada Therapeutics

Institutional investors have recently made changes to their positions in the stock. New York State Teachers Retirement System acquired a new stake in shares of Entrada Therapeutics during the first quarter worth $27,000. Acadian Asset Management LLC acquired a new position in Entrada Therapeutics in the first quarter valued at about $79,000. Tower Research Capital LLC TRC grew its stake in Entrada Therapeutics by 476.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,780 shares of the company’s stock valued at $87,000 after acquiring an additional 4,777 shares during the period. SG Americas Securities LLC grew its stake in Entrada Therapeutics by 27.7% in the fourth quarter. SG Americas Securities LLC now owns 11,714 shares of the company’s stock valued at $177,000 after acquiring an additional 2,540 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its stake in Entrada Therapeutics by 427.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock valued at $209,000 after acquiring an additional 11,965 shares during the period. 86.39% of the stock is owned by institutional investors and hedge funds.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.